Abstract B051: Marrow and peripheral blood cytokine architecture differences between pediatric patients receiving CD19- and CD22-directed CART
Bibliographic record
Abstract
Abstract Introduction: Chimeric antigen receptor T-cell (CART) targeting CD19 (CART19) have revolutionized therapy for relapsed/refractory pediatric B-cell acute lymphoblastic leukemia (B-ALL). However, not all children are cured with CD19-directed CART, leading to the use of CD22-directed CART (CART22) as an alternative therapy. To better understand differences in outcome and toxicity following CART19 and CART22 we used high-throughput protein and transcriptional techniques to understand differences in cytokine architecture. Methods: We used a proximity extension assay (Olink Signature 100 T48, Olink, Uppsala, Sweden) to measure 48 proteins from paired peripheral blood (PB) and bone marrow (BM) serum from 20 patients (N=10 CART19, N=10 CART22). We performed single cell RNA sequencing (scRNAseq) on pre-infusion peripheral blood mononuclear cells (PBMCs; N=3 CART19, N=4 CART22) and pre-infusion bone marrow mononuclear cells (BMMCs; N=3 CART19, N=4 CART22). Croypreserved cells were thawed. Approximately ten thousand cells from each sample were pooled into a single volume and then taken into a single cell RNA-Seq assay using the Chromium NextGem Single Cell 3' GEM, Library & Gel Bead Kit v3.1(10X Genomics). Sequencing libraries were run on Bioanalyzer 2100 and quantified with KAPA library quantification kit (Roche 07960140001) prior to sequencing on Illumina NovaSeq6000 with 28:10:10:90 paired-end configuration. Results: Samples were obtained from patients treated on clinical trials of CART19 (NCT01626495, NCT02906371) and CART22 (NCT02650414). There was no difference in pre-infusion disease burden between CART19 and CART22 patients. All patients who received CART22 had previously been treated with CART19 or the CD19 directed bispecific T-cell engaging antibody blinatumomab. Pre-treatment marrow serum from patients who went on to receive CART22 had higher levels of the proteins CSF3, IL10, CXCL9, IL6, CXCL8 and CXCL10, implying that previous treatment with CART19 impacted the marrow environment. Pre-treatment marrow cellular populations also differed between CART19 and CART22 patients. Patients who went on to receive CART22 had a higher proportion of CD16+ monocytes then CART19 patients. Three distinct clusters of CD16+ monocytes were identified with unique transcriptional profiles. We previously demonstrated that the anti-inflammatory cytokine IL-10 was higher in the peripheral blood of patients who went on to receive CART22. Measured IL-10 protein levels were higher in both BM and PB serum. Pre-treatment PBMC expression of IL-10 measured by scRNAseq did not differ appreciably between patients who went on to receive CART19 and those who went on to receive CART22. However, IL-10 expression in BMMCs was higher in patients who went on to receive CART22, implying that measured IL-10 differences have a marrow cellular source. Conclusions: Using high throughput protein measurement techniques and scRNAseq we demonstrate clear differences in the pre-infusion cytokine and cellular architecture of patients treated with CART19 or CART22. Citation Format: Caroline Diorio, Lahari Uppuluri, Anusha Thadi, Regina Myers, Rawan Shraim, Amanda Dinofia, Zachary Martinez, Amira Elhachimi, Joseph Fraietta, Vanessa Gonzalez, Vivian Yi, Haley Newman, Andrew Hughes, Kai Tan, Stephan Grupp, David T. Teachey. Marrow and peripheral blood cytokine architecture differences between pediatric patients receiving CD19- and CD22-directed CART [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pediatric Cancer Research; 2024 Sep 5-8; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl):Abstract nr B051.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.003 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".